Pascal Soriot, AstraZeneca CEO (Justin Tallis/Press Association via AP Images)

Icosavax buy­out caps As­traZeneca’s long search for a vac­cine plat­form

As­traZeneca is gain­ing a late-stage RSV vac­cine can­di­date as part of its pro­posed ac­qui­si­tion of Icosavax af­ter the British drug­mak­er spent two years search­ing for a plat­form that would help de­fine the di­vi­sion that en­com­pass­es its vac­cine and an­ti­bod­ies busi­ness­es.

The com­pa­ny has been “dili­gent­ly look­ing at all dif­fer­ent plat­forms” in a “rel­a­tive­ly broad” ef­fort since launch­ing the busi­ness unit in late 2021, said Iskra Re­ic, the ex­ec­u­tive vice pres­i­dent who leads As­traZeneca’s vac­cines and im­mune ther­a­pies unit, in an in­ter­view with End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.